Skip to main content
    B

    Bio-Rad Laboratories Inc (BIO)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $360.21
    -6.15 (-1.68%)

    Market Cap: $9.85B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Bio-Rad Laboratories Inc (BIO) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Bio-Rad Laboratories reported revenue of $2.58B for the fiscal year ended Dec 31, 2025, up 0.7% from the year before. That year, net income was $759.90M with a net margin of 29.4%, operating cash flow was $532.20M and free cash flow was $374.60M. The quarter ended Sep 30, 2026 had revenue of $656.40M and net income of $458.60M.

    Revenue and Margins

    The operating margin was 1.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $2.07B, a compound annual rate of 2.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$2.58B+0.7%51.9%1.8%29.4%
    Dec 2024$2.57B-3.9%53.7%10.5%-71.9%
    Dec 2023$2.67B-4.7%53.4%12.6%-23.9%
    Dec 2022$2.80B-4.1%55.9%17.2%-129.5%
    Dec 2021$2.92B+14.8%56.1%17.1%145.6%
    Dec 2020$2.55B+10.1%56.5%16.6%149.8%
    Dec 2019$2.31B+1.0%54.4%9.9%76.1%
    Dec 2018$2.29B+6.0%53.4%-4.5%16.0%
    Dec 2017$2.16B+4.4%55.0%5.5%5.7%
    Dec 2016$2.07BN/A55.0%2.7%1.3%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$2.58B$2.57B$2.67B$2.80B$2.92B$2.55B$2.31B$2.29B$2.16B$2.07B
    Cost of revenue$1.24B$1.19B$1.24B$1.23B$1.28B$1.11B$1.05B$1.07B$972.45M$929.74M
    Gross profit$1.34B$1.38B$1.43B$1.57B$1.64B$1.44B$1.26B$1.22B$1.19B$1.14B
    Research and development$275.60M$295.90M$247.40M$256.90M$260.64M$217.76M$202.71M$199.20M$250.16M$205.71M
    Operating income$47.20M$269.00M$337.80M$482.60M$500.34M$421.33M$229.66M-$103.34M$119.25M$55.72M
    Net income$759.90M-$1.84B-$637.30M-$3.63B$4.25B$3.81B$1.76B$365.61M$122.25M$26.00M
    EBITDA$144.10M$363.20M$451.60M$527.50M$524.36M$444.04M$253.51M$536.62M$120.82M$64.94M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$656.40M$651.00M$592.10M$693.20M$653.00M$651.60M$585.40M$667.50M$649.70M$638.50M$610.80M$681.12M
    Gross profit$328.60M$345.80M$309.40M$345.20M$343.40M$345.30M$306.00M$342.00M$355.90M$355.10M$325.90M$366.32M
    Operating income-$49.70M$72.60M$34.10M-$118.90M$65.30M$77.10M$23.70M$58.40M$64.50M$101.50M$44.60M$95.32M
    Net income$458.60M$371.40M-$527.10M$720.00M-$341.90M$317.80M$64.00M-$715.80M$653.20M-$2.17B$383.90M$349.73M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $1.20B exceeded cash and equivalents by $673.20M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$10.58B$9.36B$12.30B$13.50B$17.80B$12.97B$8.01B$5.61B$4.27B$3.85B
    Current assets$2.91B$3.03B$3.05B$3.16B$1.99B$2.14B$2.18B$2.02B$1.98B$1.84B
    Cash and equivalents$529.80M$488.10M$403.80M$434.21M$470.78M$662.21M$660.67M$431.53M$383.82M$456.26M
    Total liabilities$3.12B$2.79B$3.56B$3.89B$4.11B$3.09B$2.25B$1.59B$1.34B$1.27B
    Short-term debt$1.30M$1.20M$500.00K$465.00K$489.00K$1.80M$426.17M$493.00K$420.00K$334.00K
    Long-term debt$1.20B$1.20B$1.20B$1.20B$10.51M$12.26M$13.58M$438.94M$434.58M$434.19M
    Shareholder equity$7.45B$6.57B$8.74B$9.62B$13.69B$9.88B$5.76B$4.02B$2.93B$2.58B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$10.78B$10.25B$9.79B$10.58B$9.70B$10.21B$9.53B$9.36B$10.60B$9.69B$12.61B$12.30B
    Total liabilities$3.18B$3.08B$2.94B$3.12B$2.96B$3.09B$2.85B$2.79B$3.12B$2.91B$3.56B$3.56B
    Cash and equivalents$465.30M$517.00M$507.20M$531.80M$395.80M$369.30M$521.40M$488.10M$410.38M$406.91M$433.28M$403.81M
    Shareholder equity$7.60B$7.17B$6.85B$7.45B$6.74B$7.13B$6.68B$6.57B$7.49B$6.78B$9.05B$8.74B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 70.4% of operating cash flow. Share repurchases came to 78.9% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$532.20M$455.20M$374.90M$17.60M$669.46M$584.97M$285.00K$285.49M-$17.72M$216.07M
    Capital expenditures$157.60M$165.60M$156.70M$112.80M$133.75M$108.56M$98.53M$129.82M$115.13M$141.44M
    Free cash flow$374.60M$289.60M$218.20M-$95.20M$535.72M$476.41M-$98.25M$155.67M-$132.85M$74.63M
    Dividends paidN/AN/A$100.10B$68.18B$35.28B$20.20M$3.83BN/A$4.37MN/A
    Share repurchases$295.50M$203.60M$428.70M$215.70M$50.00M$100.00M$28.00M$48.91M$2.92M$0
    Investing cash flow-$189.70M-$160.20M$20.20M-$1.21B-$797.38M-$69.89M-$208.89M-$186.98M-$175.57M-$213.88M
    Financing cash flow-$283.20M-$218.80M-$425.60M$973.60M-$55.43M-$523.04M-$22.76M-$48.68M$341.00K$9.02M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$22.40M-$131.40M$108.10M$577.70M$120.90M$268.60M-$22.20M$500.80M-$22.30M-$900.00K-$22.40M$374.90M
    Capital expenditures$31.20M$32.00M$30.00M$45.80M$31.70M$45.70M$34.40M$42.90M$40.20M$42.30M$40.20M$42.27M
    Free cash flow-$53.60M-$163.40M$78.10M$531.90M$89.20M$222.90M-$56.60M$457.90M-$62.50M-$43.20M-$62.60M$332.63M
    Last 12 quarters

    Frequently Asked Questions About BIO

    What is Bio-Rad Laboratories' annual revenue?

    Bio-Rad Laboratories reported revenue of $2.58B for the fiscal year ended Dec 31, 2025.

    How fast is Bio-Rad Laboratories' revenue growing?

    Revenue was up 0.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -2.7%.

    Is Bio-Rad Laboratories profitable?

    Yes. Bio-Rad Laboratories reported net income of $759.90M for the fiscal year ended Dec 31, 2025, with a net margin of 29.4%.

    How much free cash flow does BIO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $532.20M minus capital expenditures of $157.60M produced free cash flow of $374.60M.

    How much debt does Bio-Rad Laboratories have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $1.20B, short-term debt of $1.30M and cash and equivalents of $529.80M.